é žåã¹ãã¬ã¹ã§å·ã€ãã现èã现èæ»ã§å¹çããæé€ããæ©æ§ãçºèŠ
-ãã现èã®æé€ããããæå¶ããæ°èŠåµè¬ã«ç¹ããç 究ææ-
çºè¡šã®ãã€ã³ã
1.é žåã¹ãã¬ã¹(泚ïŒ)ã§å·ã€ãã现èã现èæ»ãå¹çããåŒãèµ·ããä»çµã¿ãçºèŠããŸããã
2.ä»åã®çºèŠã¯ããããªã©ã®é¢é£çŸæ£ã®ç å 解æã®ç³žå£ã«ãªããšå ±ã«ãé žåã¹ãã¬ã¹ã§ãã¡
ããŒãžãèç©ãããã现èã®æé€ãããããæå¶ããæ°èŠåµè¬ã®éçºã«ã€ãªããããšãæåŸ
ããããŸãã
æŠèŠ
ãç§ãã¡ã®äœãæ§æãã现èã§ã¯ã掻æ§é žçŽ (泚 2)ãæ§ã ãªã¹ãã¬ã¹ã«ãããããé žåã¹ãã¬ã¹ãçããŸãã軜床ã®é žåã¹ãã¬ã¹æã«ã¯ãæé žåå¿ç(泚 3)ã掻æ§åããããšã§çŽ°èã®çåãç¶æããŸããäžæ¹ãé床ã®é žåã¹ãã¬ã¹æã«ã¯ãç©æ¥µçã«çŽ°èæ»ãèµ·ãããæå·ãåãã现èãæé€ããããšã§çäœã®æåžžæ§ãç¶æããŠããŸããããã®éãæé žåå¿çã OFF ã«ããŠãå¹çè¯ã现èæ»ãåŒãèµ·ããå¿ èŠããããŸããããããªããããã®è©³çŽ°ãªæ©æ§ã«ã€ããŠã¯ãäžæãªç¹ãå€ãæ®ãããŠããŸãã
ãæ±å倧åŠå€§åŠé¢è¬åŠç 究ç§ã®å¹³ç°ç¥ä»å©æãäžç°æ é修士ãæŸæ²¢åææãã®ç 究ã°ã«ãŒãã¯ãç¹ã«é床ã®é žåã¹ãã¬ã¹æã«ãæé žåå¿çã«éèŠãªè»¢åå å(泚 4)Nrf2 ã®æŽ»æ§åãç©æ¥µçã«æå¶ãããããšã§ã现èæ»ãå¹çããèµ·ããä»çµã¿ãçºèŠããŸãããNrf2 ã®æŽ»æ§åãæ ããããŒãŒååïŒæ³šÂ 5ïŒTAK1 ã¯ããŠãããã³åé µçŽ ïŒæ³šÂ 6ïŒRoquin-2 ã«ãã£ãŠé žåã¹ãã¬ã¹äŸåçã«ãŠãããã³åãåããå解ãããŸãã
æ¬æ©æ§ã®ç Žç¶»ã¯ããããªã©ã®æ§ã ãªç æ ã®çºçã»é²å±ãžã®å¯äžãæ³å®ãããããšãããä»åã®çºèŠã¯ãããã®ç æ 解æãããããæå¶ããæ°èŠåµè¬ã®éçºã«ç¹ããéèŠãªåºç€çç¥èŠãšãªããŸãã
ç 究ã®èæ¯
ãç§ãã¡ã®äœãæ§æãã现èã§ã¯ã代è¬ã«ããæåžžçã«ç£çããã掻æ§é žçŽ ãã玫å€ç·ãç åäœææãªã©ã®æ§ã ãªã¹ãã¬ã¹ã«æãããããšã§ãé žåã¹ãã¬ã¹ãçããŸãã軜床ã®é žåã¹ãã¬ã¹æã«ã¯ãæé žåå¿çã掻æ§åããããšã§çŽ°èã®çåãç¶æããŸããããã®ééèŠãªåœ¹å²ãæ ãã®ã転åå å NF-E2-relatedfactor 2 (Nrf2)ã§ãæé žåå¿çã«å¿ èŠãšãªãå€å²ã«ãããéºäŒåãçºçŸèªå°ããããšã§ãæé žåã·ã¹ãã ãäœåãããããšãç¥ãããŠããŸãã
äžæ¹ãé床ã®é žåã¹ãã¬ã¹æã«ã¯ãæ¢ããŠç©æ¥µçã«çŽ°èæ»ãèµ·ãããæå·ãåãã现èãæé€ããããšã§çäœã®æåžžæ§ãç¶æããŠããŸãã代衚çãªçŽ°èæ»èªå°æ©æ§ã®Â 1 ã€ããé žåã¹ãã¬ã¹å¿çæ§ã®ãããŒãŒåå Apoptosis signalregulating kinase 1 (ASK1)ãä»ãã现èæ»èªå°çµè·¯ã§ãã¹ãã¬ã¹å¿çæ§Â MAP ãããŒãŒ(泚ïŒ)çµè·¯ã®æŽ»æ§åã«ãã现èæ»ïŒã¢ãããŒã·ã¹ïŒãåŒãèµ·ããããšãç¥ãããŠããŸãããã®æãæé žåå¿çã®æŽ»æ§åã¯ã现èæ»èªå°ã«ãããéªéã«ãªã£ãŠããŸãããšãããæé žåå¿çã OFF ã«ããããšã§ã现èæ»ãå¹çããèªå°ããå¿ èŠããããŸãã
ãããé床ã®é žåã¹ãã¬ã¹æã«ããã«ããŠæé žåã·ã¹ãã ãæå¶ããã®ãããã®å ·äœçãªã¡ã«ããºã ã¯ãçŸç¶ã§ã¯ã»ãšãã©äžæã§ãã
ç 究ã®æŠèŠ
ãå¹³ç°ç¥ä»å©æãäžç°æ é修士ãæŸæ²¢åææãã®ç 究ã°ã«ãŒãã¯ãNrf2 ã®æŽ»æ§åå åãšããŠç¥ãããŠãããããŒãŒåå TAK1 ã®æ°èŠçµåå åãšããŠããŠãããã³åé µçŽ Â Roquin-2 ãåå®ããŸãããRoquin-2 ã¯Â TAK1 ããŠãããã³åããå解ã«å°ãããšã§ãNrf2 掻æ§åãæå¶ããããšãæããã«ãªããŸããã詳现ãªè§£æãããäž¡è ã®çµåããã³Â TAK1 ãŠãããã³åã«ã¯ãTAK1 å ã«ãã 4 ç®æã®ã·ã¹ãã€ã³æ®åºïŒCys96/Cys302/Cys486/Cys500ïŒããé žåã¹ãã¬ã¹æã«é žåãåããããšã§ãžã¹ã«ãã£ãçµå(泚ïŒ)ã圢æããTAK1 ã®å€éäœåãåŒãèµ·ããããšãéèŠã§ããããšã瀺åãããŸãããããŠã¹èå ç¹ç¶èœçŽ°èãªã©ã®è€æ°ã®å¹é€çŽ°èæ ªã§ãRoquin-2 ãæ¬ æãããšãããéé žåæ°ŽçŽ ãªã©ã®é žåã¹ãã¬ã¹ã«å¯Ÿããèæ§ç²åŸïŒçŽ°èæ»ã®æå¶ïŒãèªããããŸããããŸããã®æãéçå现èã§ã¯ãç¹ã«é床ã®é žåã¹ãã¬ã¹æã«Â TAK1 ã¿ã³ãã¯è³ªãå解ãããNrf2 掻æ§åãæå¶ãããŠããŸããããRoquin-2 æ¬ æ现èã§ã¯ãTAK1 å解ã®æå¶ããã³Nrf2 ã®æŽ»æ§åã®æç¶ã確èªãããŸããã
以äžã®çµæãããé床ã®é žåã¹ãã¬ã¹ã«æé²ããã现èã§ã¯ãTAK1 ã Roquin-2 ã«ãããŠãããã³åã»å解ãåããNrf2 掻æ§åãããã³æé žåå¿çã®æŽ»æ§åãæå¶ãããããšã§ãå¹çè¯ã现èæ»ãèµ·ããããšã瀺åãããŸããã
å³Â 1. Roquin-2/TAK1 ãä»ããé žåã¹ã
ãã ã¬ã¹æã®çŽ°èå¿çå¶åŸ¡æ©æ§
äœãäžçšåºŠã®é žåã¹ãã¬ã¹æã«ã¯ãTAK1 ã Nrf2 ãä»ããŠæé žåã·ã¹ãã ã掻æ§åããããšã§ã现èçåãç¶æããã
äžæ¹ãé床ã®é žåã¹ãã¬ã¹æã«ã¯ãTAK1 ã®Â 4 ç®æã®ã·ã¹ãã€ã³æ®åºãé žåãããŠãžã¹ã«ãã£ãçµåïŒ-S-S-ïŒã圢æããTAK1 å€éäœåãåŒãèµ·ããããšã§ãRoquin-2 ã®çµåããã³ãŠãããã³ååå¿ãä¿é²ãããããŠãããã³åãåãã TAK1 ãå解ãããæé žåã·ã¹ãã ãåããªããªãäžæ¹ã§ãASK1 ãªã©ã®çŽ°èæ»èªå°æ©æ§ã掻æ§åããããšã§ãå¹çè¯ã现èæ»ãåŒãèµ·ããããã
ä»åŸã®å±æ
ãé žåã¹ãã¬ã¹ã«äŒŽã£ãŠç©æ¥µçã«çŽ°èæ»ãèµ·ããæ©æ§ã¯ããšãããã现èã®ããåæå¶ã«éèŠã§ããé žåã¹ãã¬ã¹ãèç©ãã现èãé©åã«çŽ°èæ»ãèµ·ãããŠé€å»ãããªããªããšãDNA æå·ã«ããããåãã転移ã®ä¿é²ãªã©ã®ããæªæ§åãèµ·ããããšãç¥ãããŠããŸããå®éã«ãããã€ãã®çš®é¡ã®ããã§ãTAK1 ã®çºçŸäžæã Nrf2 ã®æŽ»æ§åä¿é²ããããã®å¢æªã«å¯äžããããšã瀺ãå ±åãããããšãããä»åŸã¯ãæ¬æ©æ§ãçºçã»å¢æªã®æå¶ã«éèŠãªåœ¹å²ãæ ã£ãŠããããã®çš®é¡ã®ç¹å®ãè¡ãããšã§ãå®éã«ãã®éèŠæ§ãæ€èšŒããå¿ èŠããããŸããããã«å°æ¥çã«ã¯ãæ¬æ©æ§ã人çºçã«æŽ»æ§åããææ³ã®éçºã«ãããããã®äºé²ã»æ²»çãªã©ã«ã€ãªããããšãæåŸ ãããŸãã
çšèªèª¬æ
泚1. é žåã¹ãã¬ã¹
掻æ§é žçŽ ãªã©ã«ãã£ãŠåŒãèµ·ããããé žååå¿ã«ããåŒãèµ·ãããããçäœã«ãšã£ãŠæ害ãªäœçšã®ããšãDNAãã¿ã³ãã¯è³ªãè質ãªã©ã®çäœååãé žåãããããšã§ã现èæ©èœé害ãçããæ§ã ãªçŸæ£ã®çºçãèåã®èŠå ãšãªãã
Â
泚2. 掻æ§é žçŽ
ããã³ã³ããªã¢åŒåžã®å¯ç£ç©ãšããŠããããã¯Â NADPH ãªãã·ããŒãŒãªã©ã®é µçŽ çãªåãã«ãã£ãŠã现èå ã«çããåå¿æ§ã®é«ãé žçŽ ååçš®ã®ç·ç§°ã现èå å€ããã®æ§ã ãªã¹ãã¬ã¹ã«æãããããšã§ãããã«ç£çã亢é²ããããšãç¥ãããŠãããDNA ãã¿ã³ãã¯è³ªãªã©ãé žåããæ©èœé害ãåŒãèµ·ããããšã§ãæ§ã ãªçŸæ£ãèåã®åå ãšãªãã
Â
泚3. æé žåå¿ç
掻æ§é žçŽ ãªã©ã®é žåã¹ãã¬ã¹ã®èŠå ãšãªãé žåç©è³ªã®é€å»ããããã¯é žå修食ãªã©ã«äŒŽãååæ©èœç°åžžãžã®æµæãæ¹åãšãã£ããé žåã¹ãã¬ã¹ã«å¯Ÿããçäœã®é²åŸ¡åå¿ã
Â
泚4. 転åå å
DNA ã®ç¹å®é åã«çµåããéºäŒåã®è»¢åã»çºçŸãå¶åŸ¡ããååã
Â
泚5. ãããŒãŒåå
åºè³ªã«ã¢ããã·ã³äžãªã³é žïŒATPïŒã®æ«ç«¯ãªã³é žåºãå°å ¥ããåå¿ïŒãªã³é žåïŒã觊åªããé µçŽ ã现èå ã®æ å ±ïŒã·ã°ãã«ïŒãäŒéããéèŠãªåããæã€ã
Â
泚6. ãŠãããã³åé µçŽ
ãŠãããã³ã¯ã76 åã®ã¢ããé žãããªãæ¯èŒçååéã®å°ããã¿ã³ãã¯è³ªã§ãé µçŽ çåå¿ã«ãã£ãŠãåéäœïŒã¢ããŠãããã³ïŒãããã¯å€éäœïŒããªãŠãããã³ïŒãšããŠãåºè³ªã¿ã³ãã¯è³ªã®ãªãžã³æ®åºã«çµåããããã®é µçŽ åå¿ãæ ãã®ãããŠãããã³åé µçŽ ã§ããããŠãããã³ã®çµåæ§åŒã®éãã«ãã£ãŠãåºè³ªã¿ã³ãã¯è³ªã«äžããå¹æã圱é¿ãç°ãªããåºè³ªã¿ã³ãã¯è³ªã®å解ã DNA 修埩ãå°èè茞éãã·ã°ãã«äŒéãªã©ãå€æ§ãªççæ©èœã®å¶åŸ¡ã«é¢ãã£ãŠããããRoquin-2 ã«ãããŠãããã³åã®æ§åŒã§ãã K48 åããªãŠãããã³å修食ã¯ãäž»ã«ã¿ã³ãã¯è³ªå解ãèªå°ããã·ã°ãã«ã«ãªãããšãç¥ãããŠããã
Â
泚7. MAP ãããŒãŒ
Mitogen-activated protein kinaseïŒçŽ°èåè£ä¿é²å å掻æ§åãããã€ã³ãããŒãŒïŒã®ç¥ã§ã现èåè£ä¿é²å åã§åŠçãã现èãå¢æ®ããéã«æŽ»æ§åãããããŒãŒãšããŠÂ ERK (Extracellular signal-regulated kinase)ãåå®ãããçµç·¯ããããã®ãããªååãä»ãããããç矩ã«ã¯Â ERK1/2 ã®ã¿ãæãããåºçŸ©ã«ã¯ãæ§ã ãªã¹ãã¬ã¹ã«å¿çããŠæŽ»æ§åãã JNK (c-Jun N-terminal kinase)ã p38 ãå«ãŸãããããã¯ã¹ãã¬ã¹å¿çæ§Â MAP ãããŒãŒãšåŒã°ããã现èå æ å ±ïŒã·ã°ãã«ïŒäŒéã«ãããŠäžå¿ç圹å²ãæãããã·ã°ãã«äŒéãå®è¡ãããããŒãŒã§ããã
Â
泚8. ãžã¹ã«ãã£ãçµå
2 çµã®ããªãŒã«ïŒ-SHïŒãé žåãåããŠå ±æçµåããããšã§åœ¢æãããçµåïŒ-S-S-ïŒãã·ã¹ãã€ã³æ®åºã«ã¯ããªãŒã«åºãååšãããããé žååå¿ã«ãã£ãŠã·ã¹ãã€ã³æ®åºå士ããžã¹ã«ãã£ãçµåã圢æããããšãç¥ãããã